Trial intelligence / Profile preview

Optimization of HAART for Chinese

NCT02945163Phase 4Completed

Start
Mar 2018
Primary completion
Jun 2019
Modality
Small Molecules
Countries
1
01

Overview

Phase 4, randomised trial of tenofovir disoproxil fumarate and efavirenz in human immunodeficiency virus infection (HIV) (2 arms). Primary endpoint: Percentage of patients with HIV RNA<50 Copies/ml at 48 weeks. Started Mar 2018; status: completed.

02

Drugs

tenofovir disoproxil fumarateefavirenz
03

Conditions

human immunodeficiency virus infection (HIV)

Beyond the preview

Go deeper on NCT02945163.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02945163.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call